vs

Side-by-side financial comparison of AXCELIS TECHNOLOGIES INC (ACLS) and CONMED Corp (CNMD). Click either name above to swap in a different company.

CONMED Corp is the larger business by last-quarter revenue ($317.0M vs $238.3M, roughly 1.3× AXCELIS TECHNOLOGIES INC). AXCELIS TECHNOLOGIES INC runs the higher net margin — 14.4% vs 4.4%, a 10.0% gap on every dollar of revenue. On growth, CONMED Corp posted the faster year-over-year revenue change (-1.3% vs -5.6%). Over the past eight quarters, CONMED Corp's revenue compounded faster (-2.3% CAGR vs -2.8%).

Axcelis Technologies, Inc. is an American company engaging in the design, manufacture, and servicing of capital equipment for the semiconductor manufacturing industry worldwide. It produces ion implantation systems, including high and medium current implanters, and high energy implanters, and curing systems used in the fabrication of semiconductor chips. The company was incorporated in 1995 and is headquartered in Beverly, Massachusetts, United States.

The CONMED Corporation is a publicly traded American manufacturer of medical equipment and surgical devices, primarily in the orthopedic, laparoscopic and general surgery, and patient care areas. CONMED's headquarters is in Largo, Florida. Prior to July 2022, it was in Utica, New York. CONMED embraces a people-first culture that starts with a mission to support their healthcare partners and the patients they serve. They have manufacturing facilities in the United States and Mexico, offices in...

ACLS vs CNMD — Head-to-Head

Bigger by revenue
CNMD
CNMD
1.3× larger
CNMD
$317.0M
$238.3M
ACLS
Growing faster (revenue YoY)
CNMD
CNMD
+4.3% gap
CNMD
-1.3%
-5.6%
ACLS
Higher net margin
ACLS
ACLS
10.0% more per $
ACLS
14.4%
4.4%
CNMD
Faster 2-yr revenue CAGR
CNMD
CNMD
Annualised
CNMD
-2.3%
-2.8%
ACLS

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ACLS
ACLS
CNMD
CNMD
Revenue
$238.3M
$317.0M
Net Profit
$34.3M
$13.8M
Gross Margin
47.0%
57.9%
Operating Margin
15.2%
8.0%
Net Margin
14.4%
4.4%
Revenue YoY
-5.6%
-1.3%
Net Profit YoY
-31.3%
129.1%
EPS (diluted)
$1.11
$0.45

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACLS
ACLS
CNMD
CNMD
Q1 26
$317.0M
Q4 25
$238.3M
$373.2M
Q3 25
$213.6M
$337.9M
Q2 25
$194.5M
$342.3M
Q1 25
$192.6M
$321.3M
Q4 24
$252.4M
$345.9M
Q3 24
$256.6M
$316.7M
Q2 24
$256.5M
$332.1M
Net Profit
ACLS
ACLS
CNMD
CNMD
Q1 26
$13.8M
Q4 25
$34.3M
Q3 25
$26.0M
$2.9M
Q2 25
$31.4M
$21.4M
Q1 25
$28.6M
$6.0M
Q4 24
$50.0M
Q3 24
$48.6M
$49.0M
Q2 24
$50.9M
$30.0M
Gross Margin
ACLS
ACLS
CNMD
CNMD
Q1 26
57.9%
Q4 25
47.0%
58.5%
Q3 25
41.6%
49.2%
Q2 25
44.9%
55.0%
Q1 25
46.1%
55.3%
Q4 24
46.0%
57.3%
Q3 24
42.9%
56.5%
Q2 24
43.8%
55.3%
Operating Margin
ACLS
ACLS
CNMD
CNMD
Q1 26
8.0%
Q4 25
15.2%
9.8%
Q3 25
11.7%
3.5%
Q2 25
14.9%
11.1%
Q1 25
15.1%
5.0%
Q4 24
21.6%
15.2%
Q3 24
18.3%
20.7%
Q2 24
20.6%
14.2%
Net Margin
ACLS
ACLS
CNMD
CNMD
Q1 26
4.4%
Q4 25
14.4%
Q3 25
12.2%
0.8%
Q2 25
16.1%
6.3%
Q1 25
14.8%
1.9%
Q4 24
19.8%
Q3 24
18.9%
15.5%
Q2 24
19.8%
9.0%
EPS (diluted)
ACLS
ACLS
CNMD
CNMD
Q1 26
$0.45
Q4 25
$1.11
$0.54
Q3 25
$0.83
$0.09
Q2 25
$0.98
$0.69
Q1 25
$0.88
$0.19
Q4 24
$1.54
$1.09
Q3 24
$1.49
$1.57
Q2 24
$1.55
$0.96

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACLS
ACLS
CNMD
CNMD
Cash + ST InvestmentsLiquidity on hand
$374.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.0B
Total Assets
$1.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACLS
ACLS
CNMD
CNMD
Q1 26
Q4 25
$374.3M
Q3 25
$449.6M
Q2 25
$549.8M
Q1 25
$587.1M
Q4 24
$571.3M
Q3 24
$579.4M
Q2 24
$548.3M
Total Debt
ACLS
ACLS
CNMD
CNMD
Q1 26
Q4 25
$834.2M
Q3 25
$853.0M
Q2 25
$881.1M
Q1 25
$891.4M
Q4 24
$905.1M
Q3 24
$940.1M
Q2 24
$965.2M
Stockholders' Equity
ACLS
ACLS
CNMD
CNMD
Q1 26
Q4 25
$1.0B
$1.0B
Q3 25
$1.0B
$1.0B
Q2 25
$1.0B
$1.0B
Q1 25
$1.0B
$977.6M
Q4 24
$1.0B
$962.7M
Q3 24
$975.6M
$932.9M
Q2 24
$934.9M
$881.8M
Total Assets
ACLS
ACLS
CNMD
CNMD
Q1 26
Q4 25
$1.4B
$2.3B
Q3 25
$1.4B
$2.3B
Q2 25
$1.3B
$2.3B
Q1 25
$1.3B
$2.3B
Q4 24
$1.3B
$2.3B
Q3 24
$1.3B
$2.3B
Q2 24
$1.3B
$2.3B
Debt / Equity
ACLS
ACLS
CNMD
CNMD
Q1 26
Q4 25
0.81×
Q3 25
0.85×
Q2 25
0.88×
Q1 25
0.91×
Q4 24
0.94×
Q3 24
1.01×
Q2 24
1.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACLS
ACLS
CNMD
CNMD
Operating Cash FlowLast quarter
$-6.6M
Free Cash FlowOCF − Capex
$-8.9M
FCF MarginFCF / Revenue
-3.7%
Capex IntensityCapex / Revenue
1.0%
Cash ConversionOCF / Net Profit
-0.19×
TTM Free Cash FlowTrailing 4 quarters
$107.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACLS
ACLS
CNMD
CNMD
Q1 26
Q4 25
$-6.6M
$46.3M
Q3 25
$45.4M
$53.7M
Q2 25
$39.7M
$29.1M
Q1 25
$39.8M
$41.5M
Q4 24
$12.8M
$43.3M
Q3 24
$45.7M
$51.2M
Q2 24
$40.1M
$43.3M
Free Cash Flow
ACLS
ACLS
CNMD
CNMD
Q1 26
Q4 25
$-8.9M
$41.2M
Q3 25
$43.3M
$48.5M
Q2 25
$37.7M
$23.4M
Q1 25
$34.8M
$37.8M
Q4 24
$8.1M
$39.3M
Q3 24
$41.8M
$47.8M
Q2 24
$38.1M
$39.7M
FCF Margin
ACLS
ACLS
CNMD
CNMD
Q1 26
Q4 25
-3.7%
11.0%
Q3 25
20.3%
14.4%
Q2 25
19.4%
6.8%
Q1 25
18.1%
11.8%
Q4 24
3.2%
11.4%
Q3 24
16.3%
15.1%
Q2 24
14.8%
12.0%
Capex Intensity
ACLS
ACLS
CNMD
CNMD
Q1 26
Q4 25
1.0%
1.4%
Q3 25
0.9%
1.5%
Q2 25
1.0%
1.7%
Q1 25
2.6%
1.2%
Q4 24
1.8%
1.2%
Q3 24
1.5%
1.1%
Q2 24
0.8%
1.1%
Cash Conversion
ACLS
ACLS
CNMD
CNMD
Q1 26
Q4 25
-0.19×
Q3 25
1.75×
18.78×
Q2 25
1.27×
1.36×
Q1 25
1.39×
6.88×
Q4 24
0.26×
Q3 24
0.94×
1.05×
Q2 24
0.79×
1.44×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACLS
ACLS

Products$224.6M94%
Services$13.7M6%

CNMD
CNMD

Segment breakdown not available.

Related Comparisons